Pred Mild Eye Drops Recalled Due to Failed Stability Specifications

Key Takeaways:

• The US Food and Drug Administration (FDA) has issued a voluntary Class III recall for Pred Mild, prednisolone acetate ophthalmic suspension, 10mL. The affected batches have been identified as Lots 402805 and 407596 (expiration August 2026), affecting 2736 bottles.
• The recall was initiated by AbbVie Inc due to failed stability specifications, a quality issue that is not likely to cause adverse health consequences.
• Pred Mild eye drops are used to treat eye inflammation as well as eye allergies.

The FDA has issued a Class III recall for Pred Mild eye drops, prednisolone acetate ophthalmic suspension, 10mL, affecting 2736 bottles. This medication is being recalled by AbbVie Inc based in Noth Chicago, Illinois. The recall was initiated on May 18, 2026, and received a Class III classification on May 27, 2026. A Class III classification means the use of this product is not likely to cause adverse health consequences.

The recall was initiated due to the product’s failure to meet stability specifications, specifically affecting Lots 402805 and 407596, which will expire in August 2026. AbbVie Inc sent out a public notice via letter; no public press release has been issued for this recall.

Pred Mild eye drops are a prescription medication used to treat mild to moderate eye allergies. They are also used to reduce eye inflammation caused by chemicals, heat, and infection. Pharmacists should identify and quarantine Lots 402805 and 407596, remove them from inventory, and coordinate with prescribers to provide an alternative supply.

Reference

FDA. Enforcement Report. June 3, 2026. Accessed June 3, 2026. https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=220500